Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-775-8 | CAS number: 1951-97-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Piperazine dihydrochloride (CAS No 142-64-3) and piperazine phosphate (CAS No 1951-97-9) belong to the same catergory of piperazine salts. Both the salts have the core funational group of the parent compound Piperazine . In medicine, piperazine is used in the form of the hexahydrate or as the citrate, tartrate, phosphate (1951-97-9), dihydrochloride or adipate. Thus, piperazine dihydrochloride and piperazine phosphate can be considered as belonging to the same category of chemicals.
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Reference Type:
- other: study report
- Title:
- European Union Risk Assessment Report : Piperazine
- Author:
- European Chemicals Bureau
- Year:
- 2 005
- Bibliographic source:
- 3rd Priority List Volume: 56;Final Report, 2005
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other:
- Principles of method if other than guideline:
- Data is from Covance Laboratories Ltd. Report CHE.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Piperazine dihydrochloride
- EC Number:
- 205-551-2
- EC Name:
- Piperazine dihydrochloride
- Cas Number:
- 142-64-3
- IUPAC Name:
- piperazine dihydrochloride
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- pig
- Strain:
- not specified
- Sex:
- male/female
Administration / exposure
- Route of administration:
- other: gastric intubation
- Vehicle:
- not specified
- Details on exposure:
- Two male and two female pigs were administered a single dose of 14C-piperazine at a nominal dose of 300 mg/kg bw and the excretion of radiolabeled material in urine and faeces was followed for up to 7 days in two animals.
- Duration and frequency of treatment / exposure:
- 7 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
300 mg/kg bw
- No. of animals per sex per dose / concentration:
- two male and two female pigs
- Control animals:
- not specified
- Details on study design:
- By means of thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and by liquid chromatography-mass spectroscopy (LC-MS) attempts were made to characterise the labelled material present in urine, faeces, as well as in tissues, and was mostly found to initially consist of unchanged piperazine. In the urine collected 0-24 h, 82-83% of the peak activity co-chromatographed with piperazine in HPLC or TLC. By the use of LC-MS for the radioactive residues found in tissue, the validity of the results from the chromatographic analysis could be confirmed, although there were some discrepancies between the HPLC and the TLC data. The nature of the labelled conversion products derived from piperazine was not determined, and the proportion of such metabolites in the urine increased with time to reach about 40-50% of the remaining activity in the 144-168 h urine as judged by HPLC and TLC. In the kidney the fraction unidentified metabolites increased from about 20% at 12 h post dosing to 80-90% of the remaining activity at 96 h post dosing. Since carbon dioxide in exhaled air was not collected, minor metabolic conversion of piperazine to this metabolic end product cannot be excluded.
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- In the pig piperazine is readily absorbed from the gastrointestinal tract,
- Type:
- excretion
- Results:
- The principal route of excretion of piperazine and its metabolites is via urine, with a minor fraction recovered from faeces (16%).
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- In the pig piperazine is readily absorbed from the gastrointestinal tract, and the major part of the resorbed compound is excreted as unchanged piperazine during the first 48 h. An oral absorption of 100 % is brought forward to the exposure assessment. Default absorption values of 100 % are assumed for dermal and inhalatory exposure.
- Details on distribution in tissues:
- Of the sampled tissues, the highest activity was found in kidneys and liver.
- Details on excretion:
- The principal route of excretion of piperazine and its metabolites is via urine, with a minor fraction recovered from faeces (16%). However, about one forth of a single administered oral dose is retained in the tissues after 7 days, some of which seems to consist of unidentified conversion products.
56% of the total activity was eliminated via urine during 7 days, out of which 46% was excreted in the first 24 h. During the time of observation, 16% was excreted in faeces, while; again, most of the dose (8%) was eliminated during the first 24 h.
However, whereas elimination of the activity in kidney was rapid, with only some 3% remaining of the 12 h value post dosing, the excretion from liver, skeletal muscle, fat and skin was considerably slower with 10, 11, 24, 25%, respectively, remaining after 7 days in comparison with the 12 h levels.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- N-mononitrosopiperazine have been identified.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The substance, piperazine, do not have a bioaccumulation potential based on the experimental study result. - Executive summary:
In the pig piperazine is readily absorbed from the gastrointestinal tract, and the major part of the resorbed compound is excreted as unchanged piperazine during the first 48 h. An oral absorption of 100 % is brought forward to the exposure assessment.Default absorption values of 100 % are assumed for dermal and inhalatory exposure. The principal route of excretion of piperazine and its metabolites is via urine, with a minor fraction recovered from faeces (16%). However, about one forth of a single administered oral dose is retained in the tissues after 7 days, some of which seems to consist of unidentified conversion products. Besides N-mononitroso piperazine, no other metabolites have been identified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.